Proteomics technology and investment research

Technical bottleneck

Physics: why it's hard — the five-platform fragmentation

Proteins are harder than DNA for three fundamental reasons:

1. No amplification: DNA can be copied (PCR) — a single molecule becomes billions. Proteins cannot be amplified. Every molecule must be detected directly, requiring attomole-to-zeptomole sensitivity.
2. Dynamic range: The plasma proteome spans >10 orders of magnitude in concentration (albumin at ~40 mg/mL vs. cytokines at ~1 pg/mL). No single detector can cover this range without depletion or fractionation.
3. Proteoforms: A single gene can produce dozens of protein variants via alternative splicing, post-translational modifications (PTMs — phosphorylation, glycosylation, acetylation, ubiquitination, cleavage). Measuring "amount of protein X" misses which proteoform is present. Cancer signaling depends on which phosphorylated form, not total abundance.

Five platforms attack these problems with different physics:

1. Mass spectrometry (DIA / TMT — Thermo, Bruker)

The unbiased workhorse. Proteins are digested into peptides, separated by LC, ionized, and fragmented in the mass spectrometer. Data-independent acquisition (DIA) fragments everything in a mass window systematically, enabling retrospective re-analysis. TMT (tandem mass tags) multiplexes up to 18 samples with isobaric labels. The bottleneck: dynamic range limited to ~4–5 orders of magnitude without extensive fractionation; low-abundance proteins in plasma (pg/mL) are below detection without depletion. One run = 6,000–10,000 proteins in cell lysate, ~1,000–2,000 in undepleted plasma.

2. Olink PEA (Proximity Extension Assay — Thermo Fisher, acquired 2024)

Pairs of antibodies bind adjacent epitopes on the same protein; their conjugated DNA oligos hybridize and extend, creating a unique PCR-amplifiable barcode. Dual-binding requirement gives high specificity (reduces cross-reactivity vs. single-antibody methods). The bottleneck: antibody-based — limited to proteins with good antibody pairs (~5,400 in Explore HT panel). PTMs or conformational changes that block epitope binding are invisible. Strengths: minimal sample volume (1 μL plasma), excellent reproducibility, used in UK Biobank and pharma trials.

3. SomaScan (SOMAmer aptamers — Illumina/Standard BioTools, acquired from SomaLogic)

Modified DNA aptamers (SOMAmers) with slow off-rates bind proteins with high affinity. Released aptamers are quantified on microarrays or via NGS. Current plex: ~7,000–11,000 proteins. The bottleneck: concordance with Olink for overlapping proteins is modest (median correlation ~0.26–0.30) — the two platforms often give different biological conclusions for the same protein. Platform-specific effects mean you cannot directly compare Olink and SomaScan data without cross-validation.

4. Single-molecule protein sequencing — Nautilus Voyager (NAUT)

Proteins are immobilized on a single-molecule array and exposed iteratively to a library of affinity reagents against short linear epitopes. The pattern of binding events across cycles creates a unique "fingerprint" that identifies the protein and its proteoform. The bottleneck: still in Early Access Program (2026); throughput and proteome coverage are developing. Strength: proteoform-level resolution — can distinguish tau splice variants and phosphorylation states in Alzheimer's research that bulk methods blur together.

5. Single-molecule sequencing — Quantum-Si Platinum/Proteus (QSI)

Semiconductor-chip-based protein sequencer. Immobilized proteins/peptides undergo sequential N-terminal amino acid cleavage by exopeptidases; fluorescently labeled amino acids are detected via CMOS imaging. Produces actual sequence reads (tens of amino acids) — the closest analog to DNA sequencing. The bottleneck: short read lengths mean identification relies on reference databases; single-pass error rates are higher than NGS for DNA. Strengths: protein-level variant validation, PTM mapping, drug target characterization. Proteus instrument launch H2 2026.

Economic constraints

• No single dominant platform: Unlike Illumina's ~80–85% share in sequencing, no proteomics platform exceeds ~30–40% market share. This fragments instrument purchasing decisions and slows standardized clinical adoption.
• Switching costs are real but lower than sequencing: Affinity-based methods (Olink, SomaScan) have lower instrument switching costs than mass spectrometry (where methods, columns, and trained staff create lock-in). But data incompatibility between platforms (Olink vs. SomaScan) means you cannot easily merge datasets — creating de facto lock-in at the data layer.
• Single-molecule platforms are pre-revenue: Nautilus and Quantum-Si are burning cash building adoption; commercial inflection is 2027–2028 at earliest. This means the near-term investable proteomics exposure is through TMO (Olink + mass spec) and BRKR (timsTOF).

Adoption

Why it matters now

Thermo Fisher (TMO) — the proteomics conglomerate:

• Olink PEA: acquired ~$3.2B (2024), integrated into Life Sciences Solutions. Pre-acquisition Olink was high-growth ($200–300M revenue, 40%+ growth). No standalone Olink revenue disclosed post-acquisition, but proteomics is a key growth vector within TMO's $11B Life Sciences segment.
• Orbitrap mass spectrometry: the dominant high-resolution platform. New product cycle at ASMS 2026 (next-gen Orbitrap, NVIDIA AI integration).
• TMO Q1 2026: Analytical Instruments $1.71B (flat, -2% organic), Life Sciences Solutions $2.64B (+12.6%).
• [SEC] TMO 10-K FY2025: link

Illumina (ILMN) — multi-omics via SomaScan:

• Acquired SomaLogic; integrating SomaScan proteomics with NovaSeq X sequencing for multi-omics panels
• Strategic logic: every genomics customer is a potential proteomics customer — multi-omics on one platform increases switching costs
• ILMN Q1 2026: $1.09B (+5%), clinical consumables +20% ex-China

Nautilus (NAUT) and Quantum-Si (QSI):

• Pre-revenue; both building early-access partnerships
• NAUT: focused on neurodegeneration (tau proteoforms in Alzheimer's)
• QSI: Proteus launch H2 2026; oncology applications (mutational target mapping); cash runway into 2028
• These are optionality bets — if single-molecule protein sequencing achieves NGS-like adoption, the TAM is the entire proteomics market ($40B+)

Key trends

• Population-scale proteomics: UK Biobank running Olink on 500,000+ samples — creating the first population-scale proteomic reference dataset. This drives pharma adoption: if every clinical trial runs the same proteomic panel, Olink becomes the standard.
• Multi-omics integration: Genomics + proteomics on one platform (Illumina SomaScan + NovaSeq X). The selling proposition: don't just sequence the tumor — measure which proteins are actually expressed.
• Single-molecule as the NGS analog: Just as NGS displaced microarrays in genomics, single-molecule protein sequencing aims to displace affinity panels in proteomics. But the physics is harder — no PCR amplification — so the timeline is 5–10 years, not 2–3.
• Clinical proteomics: Moving from research tool to FDA-cleared assays — Olink panels for inflammatory biomarkers, mass spectrometry for therapeutic drug monitoring, protein sequencing for oncology variant calling.

Key players

Horizon

• Horizon 1 (0–2yr): Olink population-scale adoption (UK Biobank, pharma trials); SomaScan integration into Illumina workflow; TMO new Orbitrap product cycle; QSI Proteus commercial launch
• Horizon 2 (3–5yr): Clinical proteomics panels (FDA-cleared); multi-omics becomes standard in oncology trials; single-molecule platforms approach commercial scale
• Horizon 3: Single-molecule protein sequencing at population scale — $100 proteomes; real-time clinical proteomics (surgical biopsy → treatment decision in minutes)

Related Technologies

• Mass Spectrometry — the core instrument platform for unbiased proteomics
• Chromatography — prerequisite separation; LC-MS/MS is the dominant proteomics workflow
• Sequencing — multi-omics integration; affinity proteomics (Olink, SomaScan) uses NGS as the readout
• Spatial Biology — spatial proteomics via MALDI imaging MS or CosMx protein co-detection